Gapping up
In reaction to strong earnings/guidance:
- MIME +6.5%, ALTR +3.9%, XNET +3.7%, SYMC +2.5%
Other news:
- PFNX +23.8% (Pfenex announces top-line results from its PF708-301 study, which showed comparable overall profiles between PF708 and Forteo after 24 weeks of daily injection in osteoporosis patients)
- NEWR +1.8% (commences $435 mln private placement of convertible senior notes due 2023) .
Analyst comments:
- NTLA +7.8% (upgraded to Buy at Chardan Capital Markets; tgt raised to $57.50)
- CRSP +3.5% (target raised to $72.50 at Chardan Capital Markets)
- VRX +3.4% (upgraded to Buy from Neutral at Mizuho)
- ULTA +2% (upgraded to Outperform from Perform at Oppenheimer)
- PVTL +1.9% (initiated with a Buy at Goldman)
- SMG +1.2% (upgraded to Buy from Hold at SunTrust)
- MU +1.2% (target raised to $101 at Stifel)
- FGEN +1% (upgraded to Buy from Neutral at Mizuho)
- FLR +0.9% (added to US 1 List at BofA/Merrill)
![]()